Azapropazone is a nonsteroidal anti-inflammatory drug (NSAID). It is manufactured by Goldshield under the tradename Rheumox.[1]
It was available in the UK as a prescription-only drug, with restrictions due to certain contra-indications and side-effects.[2] Azopropazone has now been discontinued in the British National Formulary.
Azapropazone has a half-life of approximately 20 hours in humans and is not extensively metabolized.[3]
References
- ^ "Rheumox Capsules". South Africa Electronic Package Inserts. Archived from the original on 2008-05-15. Retrieved 2008-08-18.
- ^ "Azapropazone". Patient UK. Archived from the original on 12 April 2009.
- ^ Jones CJ (1976). "The pharmacology and pharmacokinetics of azapropazone - a review". Current Medical Research and Opinion. 4 (1): 3–16. doi:10.1185/03007997609109277. PMID 770078.
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
